This excerpt taken from the LLY 8-K filed Nov 19, 2009.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Eli Lilly and Company announced on November 13, 2009 that Steven M. Paul, M.D., executive vice president, science and technology, will retire from Lilly effective February 28, 2010. He will be succeeded by Dr. Jan Lundberg, currently executive vice president, discovery research at AstraZeneca.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.